Antibody-drug conjugates (ADCs) are primarily composed of three “modules”: an antibody (usually a monoclonal antibody), a linker, and a cytotoxic drug (payload). In recent years, ADCs have stood out among biological drugs due to their combination of the potent killing effect of chemotherapy agents and the precise targeting of antibody drugs, earning the title of … Read more
The ADC Field Is Flourishing, with new technologies evolving like a raging torrent, propelling biomedicine into a sprint mode, this is the best of times. As early as the beginning of the 20th century, Paul Ehrlich first proposed the concept of the “magic bullet”, but the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was not approved … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that it is possible to find and develop drugs that specifically target the unique structural features of pathogens, killing only the pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target … Read more
Antibody Drug Conjugates (ADCs) are a new type of targeted anti-tumor therapy. They combine the targeting capability of monoclonal antibodies with the cytotoxic effects of highly effective chemotherapeutic agents, primarily used for the treatment of various refractory cancers. ADCs precisely identify and attack cancer cells while minimizing damage to normal cells, thus exhibiting high efficiency … Read more
Payload The early developed ADCs used FDA-approved anticancer agent small molecule payloads, such as DM1 and vincristine, but these drugs have poor toxicity. Due to the large size of ADCs, it is estimated that only about 2% of ADCs are effectively internalized, thus more toxic payloads have been developed as ADC payloads, most of which … Read more
Click the blue text above to follow us IntroductionAntibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule toxins. While they possess the advantages of high targeting ability and high cytotoxicity, their structural diversity and complexity, as well as the low levels of small molecule toxins released in the circulatory system, present numerous challenges for … Read more
The tumor distribution of ADCs depends on many factors, includingthe dose itself, systemic clearance rate, antigen expression level, endocytosis rate, and the tumor’s surface area to volume ratio (S/V). Poor tissue permeability remains a major challenge for antibody treatments of solid tumors, and appropriately increasing the dosage can improve the drug’s tissue distribution and enhance … Read more
Let’s take a look at the recent hot topic of ADC drugs, and systematically learn about the review published in CancersAntibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, besides endocrine therapy and targeted drugs, metastatic breast cancer (BC) commonly uses chemotherapy as a treatment method. However, the lack of tumor specificity and toxicity … Read more
The article on Zephyr device drivers and their implementation explains that device drivers are general and reusable code modules. For the same type of device, regardless of how many instances there are, the driver code is the same. For example, on the ESP32, there are multiple ADC devices, and these ADCs are identical in hardware, … Read more
Question: >>> How to connect the analog world to the physical world? Engineers will readily provide the answer—use ADC and DAC. Analog-to-digital converters (ADC) and digital-to-analog converters (DAC) are devices that convert analog signals into digital signals or vice versa. In this area, ADI offers a comprehensive range of data converter products, with DACs covering … Read more